Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Endometriosis (Diagnosis) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Validation and Refinement of Noninvasive Diagnostic Biomarkers for Endometriosis, The ENDOmarker Protocol

NCT03161704
View directory record Official record
Conditions
Endometriosis
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
5
States / cities
New Haven, Connecticut • Augusta, Georgia • Southfield, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 10, 2026, 3:02 AM EDT
Active, not recruiting No phase listed Observational

Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance

NCT03756480
View directory record Official record
Conditions
Endometriosis, Endometrial Diseases
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
135 participants
Timeline
2020 – 2026
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 10, 2026, 3:02 AM EDT
Recruiting Phase 3 Interventional

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

NCT06439524
View directory record Official record
Conditions
Endometriosis
Interventions
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 10, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial

NCT00474851
View directory record Official record
Conditions
Endometriosis
Interventions
Norethindrone acetate + estrogens, norethindrone acetate + placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 22 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 10, 2026, 3:02 AM EDT
Completed No phase listed Observational

Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Endometriosis: Identification of Potential Relevant Biomarkers to Diagnose and Treat

NCT02973854
View directory record Official record
Conditions
Endometriosis
Interventions
Not listed
Lead sponsor
St. Louis University
Other
Eligibility
13 Years to 55 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 10, 2026, 3:02 AM EDT
Suspended Phase 3 Interventional

Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery

NCT00865488
View directory record Official record
Conditions
Ovarian Cysts, Endometriosis, Adhesions
Interventions
ADHEXIL
Biological
Lead sponsor
OMRIX Biopharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2009 · Synced Oct 10, 2026, 3:02 AM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 10, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

NCT01403038
View directory record Official record
Conditions
Folliculogenesis
Interventions
elagolix
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
20
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lonetree, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 10, 2026, 3:02 AM EDT
Completed No phase listed Observational

Validation Study for Endometriosis PRO

NCT01643122
View directory record Official record
Conditions
Endometriosis
Interventions
No drug
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Jonesboro, Arkansas • Sacramento, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 10, 2026, 3:02 AM EDT
Enrolling by invitation No phase listed Observational

PET/MRI for Evaluation of Endometriosis

NCT06377553
View directory record Official record
Conditions
Endometriosis, Endometrioma
Interventions
Radiotracer Injection, Imaging, Rectal Ultrasound Gel Injection
Drug · Diagnostic Test · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
60 participants
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 10, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

NCT04471337
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 10, 2026, 3:02 AM EDT
Completed No phase listed Observational

Predicting Endometrial Receptivity for Optimal Reproductive Management

NCT04107129
View directory record Official record
Conditions
Infertility, Female, Endometriosis
Interventions
Endometrial Biopsy, Euploid embryo transfer, Blood sample
Procedure · Other · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 10, 2026, 3:02 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Endometriosis and Microvascular Dysfunction: Role of Inflammation

NCT05069740
View directory record Official record
Conditions
Endometriosis
Interventions
Salsalate Pill, Placebo
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 10, 2026, 3:02 AM EDT
Recruiting Not applicable Interventional

Physical Therapy After Endometriosis Excision

NCT07127783
View directory record Official record
Conditions
Endometriosis, Surgery
Interventions
Active Recovery, Standard Postoperative Instructions
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 10, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

BGS649 Monotherapy in Moderate to Severe Endometriosis Patients

NCT01190475
View directory record Official record
Conditions
Endometriosis
Interventions
Active treatment with a high dose of BGS649, Active treatment with a low dose of BGS649, Placebo treatment to blind study
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 10, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

NCT00800618
View directory record Official record
Conditions
Endometriosis
Interventions
PF-02413873 100 mg QD, PF-02413873 1500 mg QD, PF-02413873 20 mg QD, PF-02413873 500 mg QD, PF-02413873 Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
New Haven, Connecticut • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 10, 2026, 3:02 AM EDT
Terminated Phase 2 Interventional Results available

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb

NCT04614246
View directory record Official record
Conditions
Endometriosis
Interventions
BAY1817080, Elagolix, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 10, 2026, 3:02 AM EDT
Recruiting Not applicable Interventional

Impact of Pelvic Pain Podcast

NCT07568834
View directory record Official record
Conditions
Chronic Pelvic Pain, Endometriosis
Interventions
Podcast
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 10, 2026, 3:02 AM EDT
Completed Phase 2 Interventional

Endometriosis Trial: Study of NBI-56418 in Endometriosis

NCT00109512
View directory record Official record
Conditions
Endometriosis
Interventions
NBI-56418 (GnRH antagonist), placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Phoenix, Arizona • San Diego, California • San Ramon, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 10, 2026, 3:02 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cardiovascular Disease Risk in Women With Endometriosis

NCT03746535
View directory record Official record
Conditions
Endometriosis
Interventions
Elagolix
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 10, 2026, 3:02 AM EDT
Recruiting Not applicable Interventional

Histologic Comparison of Ablative Techniques for Endometriosis

NCT06414083
View directory record Official record
Conditions
Endometriosis, Endometriosis-related Pain, Endometriosis Pelvic, Endometriosis; Peritoneum
Interventions
Diathermy, CO2 Laser, Argon Beam Coagulator
Device
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 10, 2026, 3:02 AM EDT
Withdrawn Phase 2 Interventional

SIRT-1 Antagonism for Endometrial Receptivity

NCT04184323
View directory record Official record
Conditions
Endometriosis, Uterine Diseases, Endometrial Diseases, Infertility Unexplained, Infertility; Female, Nonimplantation
Interventions
EX-527 (Selisistat), Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 10, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Medical Treatment of Endometriosis-Associated Pelvic Pain

NCT00229996
View directory record Official record
Conditions
Endometriosis, Pelvic Pain
Interventions
Oral Contraceptive, Depot-Leuprolide/Norethindrone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 52 Years · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 10, 2026, 3:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 10, 2026, 3:02 AM EDT